Viewing Study NCT00175279



Ignite Creation Date: 2024-05-05 @ 11:54 AM
Last Modification Date: 2024-10-26 @ 9:16 AM
Study NCT ID: NCT00175279
Status: COMPLETED
Last Update Posted: 2011-05-10
First Post: 2005-09-10

Brief Title: A Cluster Randomized Trial to Assess the Impact of Opinion Leader Endorsed Evidence Summaries on Improving Quality of Prescribing for Patients With Chronic Cardiovascular Disease
Sponsor: University of Alberta
Organization: University of Alberta

Study Overview

Official Title: A Cluster Randomized Trial to Assess the Impact of Opinion Leader Endorsed Evidence Summaries on Improving Quality of Prescribing for Patients With Chronic Cardiovascular Disease
Status: COMPLETED
Status Verified Date: 2011-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: BACKGROUND Although much has been written about the influence of local opinion leaders on clinical practice there have been few controlled studies of their effect and almost none have attempted to change prescribing in the community for chronic conditions such as congestive heart failure CHF or ischemic heart disease IHD These two conditions are common and there is very good evidence about how to best prevent morbidity and mortality - and very good evidence that quality of care is in general suboptimal Practice audits have demonstrated that about half of eligible CHF patients are prescribed ACE inhibitors and fewer still reaching appropriate target doses and less than one-third of patients with established IHD are prescribed statins with many fewer reaching recommended cholesterol targets It is apparent that interventions to improve quality of prescribing are urgently needed

HYPOTHESIS An intervention that consists of patient-specific one-page evidence summaries generated and then endorsed by local opinion leaders will be able to change prescribing practices of community-based primary care physicians

DESIGN A single centre randomized controlled trial comparing an opinion leader intervention to usual care Based on random allocation of all physicians in one large Canadian health region patients with CHF or IHD not receiving ACE inhibitors or statins respectively recruited from community pharmacies will be allocated to intervention or usual care The primary outcome is improvement in prescription of proven efficacious therapies for CHF ACE inhibitors or IHD statins within 6 months of the intervention
Detailed Description: BACKGROUND Although much has been written about the influence of local opinion leaders on clinical practice there have been few controlled studies of their effect and almost none have attempted to change prescribing in the community for chronic conditions such as congestive heart failure CHF or ischemic heart disease IHD These two conditions are common and there is very good evidence about how to best prevent morbidity and mortality - and very good evidence that quality of care is in general suboptimal Practice audits have demonstrated that about half of eligible CHF patients are prescribed ACE inhibitors and fewer still reaching appropriate target doses and less than one-third of patients with established IHD are prescribed statins with many fewer reaching recommended cholesterol targets It is apparent that interventions to improve quality of prescribing are urgently needed

HYPOTHESIS An intervention that consists of patient-specific one-page evidence summaries generated and then endorsed by local opinion leaders will be able to change prescribing practices of community-based primary care physicians

DESIGN A single centre randomized controlled trial comparing an opinion leader intervention to usual care Based on random allocation of all physicians in one large Canadian health region patients with CHF or IHD not receiving ACE inhibitors or statins respectively recruited from community pharmacies will be allocated to intervention or usual care The primary outcome is improvement in prescription of proven efficacious therapies for CHF ACE inhibitors or IHD statins within 6 months of the intervention

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
IHE102 None None None